Johnson & Johnson today announced positive results from a Phase 3 study evaluating Carvykti (ciltacabtagene autoleucel ; cilta-cel) compared with standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) for the treatment of patients with relapsed or lenalidomide-refractory multiple myeloma after one line of prior therapy.

The interim analysis showed a statistically and clinically significant improvement in overall survival (OS) for patients treated with Carvykti compared with standard therapies.

Carvykti is now the first cell therapy to significantly improve overall survival compared with standard care for myeloma patients as early as second-line treatment," said Dr. Jordan Schecter, Vice President at Johnson & Johnson Innovative Medicine.

Copyright (c) 2024 CercleFinance.com. All rights reserved.